二甲双胍(Metformin) - 药物靶点：GPD1 x PRKAB1_在研适应症：分化型甲状腺癌，抑郁症，HIV感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

HENFORMIN F.C.、ANJ 900、ANJ-900

+ [3]

靶点

GPD1 x PRKAB1

作用方式

调节剂、激活剂

作用机制

GPD1调节剂(glycerol-3-phosphate dehydrogenase 1 modulators)、PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂)

治疗领域

肿瘤内分泌与代谢疾病其他疾病+ [10]

在研适应症

分化型甲状腺癌抑郁症HIV感染+ [19]

非在研适应症

2型糖尿病缺血性卒中

原研机构

Elcelyx Therapeutics, Inc.

在研机构

Baylor College of Medicine

University of Minnesota

北京协和医院

+ [10]

非在研机构

Anji Pharmaceuticals, Inc.

The Medical University of South Carolina

National Institute on Drug Abuse

+ [2]

权益机构

安济药业（上海）有限公司

Emory University

Elcelyx Therapeutics, Inc.

+ [3]

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

登录后查看时间轴

结构/序列

分子式C4H11N5

InChIKeyXZWYZXLIPXDOLR-UHFFFAOYSA-N

CAS号657-24-9

关联

375

项与二甲双胍相关的临床试验

NCT07007221

/ Not yet recruiting临床2期IIT

Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV

Depression in HIV occurs commonly and causes poor HIV outcomes with public health implications.
Depression prevalence in HIV-infected persons is estimated at 26% compared to 5% in the general population. Adherence to antiretroviral medication is a life-saving treatment in HIV, but depression can reduce engagement in care and adherence to medication. Depression is also associated with poorer levels of viral suppression and even mortality. Overall, those with depression and HIV are less likely to return to health and remain more likely to transmit the virus. therefore, treatment of HIV is essential to prevention; lower engagement in and adherence to HIV treatment due to depression puts others at risk. This is a 3 part trial, an initial pilot, a placebo controlled pilot, and a full trial.
Part 1. Dose response, Tolerability/Acceptability of Metformin for Depression in people with HIV: To do Initial assessment of metformin for depression in people with HIV we will perform a randomized, double blind, 2-arm, 12 week randomized controlled trial to assess feasibility and acceptability of metformin for depression. We will test two doses of metformin 1000 mg daily versus 1500 mg daily.
Part 2. Preliminary Efficacy Trial of Metformin for Depression in People with HIV: This will be a two-arm, double-blind trial of metformin versus placebo in people with HIV and depression. We will randomize individuals 1:1 to metformin or placebo. Will then collect blood and rectal swabs for preliminary assessments of the mechanism of action for metformin in people with HIV and depression.
Part 3. Full efficacy factorial trial of metformin for depression and comparison/interaction with fluoxetine in people living with HIV: To assess metformin and fluoxetine as efficacious treatments for depression in people with HIV, we will conduct a 4-arm, 12-week, mechanistic, double-blinded, randomized controlled treatment trial (RCT) with an assessment of inflammation and the gut microbiome. Participants (n=400) will be HIV- positive patients on ART with comorbid depression receiving care at one of two Ugandan clinics. In addition, we will use the NIMH Research Domain Criteria (RDoC) of Acute Threat and loss under Negative Valence using biomarkers and self-reported tools.

开始日期2026-07-01

申办/合作机构

University of Minnesota

NCT07226453

/ Not yet recruiting临床2期IIT

A Target Validation and Efficacy Study of Metformin in Patients With Recurrent or Progressive Posterior Fossa Group A (PFA) Ependymoma

This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.

开始日期2026-02-28

申办/合作机构

The University of California, San Francisco

ChiCTR2500115457

/ Not yet recruitingN/AIIT

A Multicenter Randomized Controlled Study on the Effects of High Dietary Fiber Meal Replacement on Blood Glucose and Metabolic Improvements in Newly Diagnosed Type 2 Diabetes Patients with Obesity

开始日期2026-01-01

申办/合作机构

北京协和医院

[+1]

100 项与二甲双胍相关的临床结果

登录后查看更多信息

100 项与二甲双胍相关的转化医学

登录后查看更多信息

100 项与二甲双胍相关的专利（医药）

登录后查看更多信息

31,354

项与二甲双胍相关的文献（医药）

2026-12-01·MOLECULAR BIOLOGY REPORTS

Mechanisms and therapeutic strategies of ferroptosis in Diabetic-Associated Cognitive Dysfunction: focus on the crosstalk with apoptosis, autophagy, and pyroptosis

Review

作者: Jiang, Yayi ; Zhou, Jianlong ; Yue, Rensong ; Shi, Wenxiang

Diabetes-associated cognitive dysfunction (DACD), a serious central nervous system complication of diabetes mellitus, poses a heavy global burden due to its intricate pathogenesis and lack of effective therapies. Mounting evidence identifies programmed cell death (PCD) as a pivotal driver of DACD progression. This review systematically elaborates on the molecular mechanisms of various PCD modalities (including apoptosis, autophagy, pyroptosis, and ferroptosis) in DACD, with a particular focus on the role of ferroptosis as a core pathogenic mechanism. Hyperglycemia disrupts cerebral iron homeostasis, induces mitochondrial dysfunction and oxidative stress, leading to inhibition of glutathione peroxidase 4 (GPX4) activity and accumulation of lipid peroxides. This cascade ultimately triggers ferroptosis in neurons, glial cells, and the blood-brain barrier, resulting in impaired synaptic plasticity and cognitive decline. Furthermore, the review delineates the complex interactive regulatory network between ferroptosis and other PCD forms (e.g., autophagy, pyroptosis), which can converge into the coordinated cell death program of PANoptosis. Intervention strategies targeting ferroptosis, such as iron chelators (deferoxamine), antioxidants (N-acetylcysteine), GPX4 activators, natural products (resveratrol, curcumin), repurposed traditional medicines (liraglutide, metformin), and non-pharmaceutical interventions (exercise, electroacupuncture), have demonstrated significant potential in improving cognitive function in preclinical models. This review aims to provide novel insights into the pathophysiology of DACD and establish a theoretical foundation for developing precise therapeutic strategies centered on targeting ferroptosis.

2026-07-01·Value in Health Regional Issues

Retail Sales of Drugs for Diabetes, Dyslipidemia, and Hypertension in Chile Under 2 Health Policies

Article

作者: Arteaga, Oscar ; Castillo-Laborde, Carla

OBJECTIVES:

The retail market represents 60% of the pharmaceutical market in Chile. Medicines for diabetes, dyslipidemia, and hypertension are among the most commonly used by the Chilean population, and these conditions have been central to health policies aimed at improving access and coverage. This study aimed to analyze the effects of the implementation of the Explicit Health Guarantees program and the Pharmaceutical Fund on retail sales of drugs for hypertension, diabetes, and dyslipidemia.

METHODS:

Drugs related to the 3 conditions were classified using Anatomical Therapeutic Chemical codes. Interrupted time-series analyses were conducted to identify changes in retail sales trends (physical and monetary units) between 2000 and 2020. Key drugs for each condition were also analyzed in greater detail.

RESULTS:

From 2000 to 2020, hypertension drugs dominated sales in physical units, whereas since 2016, diabetes drugs have led in monetary terms. After the Explicit Health Guarantees program was introduced in 2005, sales in physical units rose for diabetes (trend) and dyslipidemia drugs (trend and level). Monetary sales declined for hypertension (level and trend) and dyslipidemia (level) and increased for diabetes (trend). In 2014, with the Pharmaceutical Fund, sales in physical units decreased for dyslipidemia (trend) and increased for hypertension (level). In monetary terms, dyslipidemia sales declined (trend), and hypertension sales rose (level and trend). Brand-name drug preference in retail remains strong, even when multiple unbranded generics are available, such as metformin, losartan, and atorvastatin.

CONCLUSIONS:

Despite public-sector policies, retail sales of these drugs increased over time, although growth slowed during the second decade.

2026-06-01·TISSUE & CELL

Dictyota ciliolata ameliorates hyperglycemia, oxidative stress, and inflammation via modulation of metabolic and signaling pathways in diabetic rats

Article

作者: Ghanem, Aml ; Hathout, Amira ; Salem, Aya ; Elebeedy, Dalia ; Fayad, Eman ; Alshaya, Dalal Sulaiman ; Rizk, Hanan A ; El-Mekkawy, Haitham Ibrahim ; Doghish, Ahmed S ; Ali, Amina Rashad ; Salih, Karimeldin M A ; Aljumaa, Maha A ; Mohammed, Osama A

Diabetes mellitus, marked by chronic hyperglycemia and systemic inflammation, causes oxidative stress and multi-organ damage. Marine macroalgae like Dictyota ciliolata contain polyphenols and flavonoids with potential therapeutic effects on metabolic disorders. This study examined the antidiabetic, hepatoprotective, antioxidant, and anti-inflammatory effects of Dictyota ciliolata extract in alloxan-induced diabetic rats. Adult male Wistar rats were allocated into four groups: normal control, diabetic control, diabetic treated with metformin (5 mg/kg), and diabetic treated with Dictyota ciliolata extract (200 mg/kg) for 21 days. Assessments included fasting blood glucose, serum insulin, liver enzymes (ALT, AST, ALP), lipid profile, oxidative stress biomarkers (MDA, SOD, CAT, GPx), pro-inflammatory cytokines (IL-6, TNF-α), and transcription factors (NF-κB). Gene expression of metabolic regulators (PPAR-γ, GLUT4, IRS-1, Nrf2, AMPK) was analyzed via qRT-PCR. Histopathological examination of the liver and pancreas was conducted to assess tissue-level effects. Treatment with Dictyota ciliolata reduced fasting blood glucose by approximately 38 % and increased serum insulin levels by 55 % compared with diabetic controls. The extract restored liver enzyme profiles and lipid parameters while increasing antioxidant enzyme activities by more than 40 % and significantly reducing lipid peroxidation. Furthermore, the extract modulated the levels of inflammatory cytokines. Gene expression analysis confirmed upregulation of PPAR-γ (0.70-fold), GLUT4 (1.42-fold), AMPK (1.17-fold), IRS-1 (1.36-fold), and Nrf2 (1.49-fold) relative to diabetic controls. Histopathological findings supported the biochemical results, revealing preserved hepatic architecture with limited pancreatic recovery. Dictyota ciliolata ethanolic extract exerts multifaceted protective effects in diabetic conditions via regulation of glycemia, oxidative stress, and inflammatory signaling. These findings highlight its potential as a natural therapeutic candidate for diabetes management.

2,810

项与二甲双胍相关的新闻（医药）

2026-02-27

·Antibody Research

2 型糖尿病三期临床试验，礼来GLP-1小分子激动剂orforglipron击败口服司美格鲁肽，安全性稍逊，跟用药剂量不无关系

▎追溯 2026年2月26日，礼来公布orforglipron三期临床试验ACHIEVE-3结果，ACHIEVE-3是首个头对头3期临床试验，旨在评估口服小分子GLP-1受体激动剂orforglipron （无需限制食物和饮水）与口服索玛鲁肽在二甲双胍控制不佳的2型糖尿病成人患者中的安全性和有效性。这项为期52周的试验共纳入1698名受试者，分为四个治疗组：orforglipron 12 mg组和36 mg组，以及口服司美格鲁肽7 mg组和14 mg组。同时在《The Lancet》发表详细实验数据。在ACHIEVE-3研究中，orforglipron在主要终点和所有关键次要终点方面均优于口服索玛鲁肽，显著改善了糖化血红蛋白（A1C）和体重。 7mg司美格鲁肽、14mg司美格鲁肽、12mg Orforglipron、36mg Orforglipron治疗52周的HbA1c分别降低1.23%、1.47%、1.71%、1.91%。（治疗方案估计值） (A) Change from baseline in HbA1c at 52 weeks from ANCOVA with multiple imputation by treatment for missing HbA1c data at 52 weeks (treatment regimen estimand). (B) Change from baseline in HbA1c over time. Data are observed mean (SE), with MBE (SE) and MMRM analysis (efficacy estimand) shown in the side panel. 在体重方面，7mg司美格鲁肽、14mg司美格鲁肽、12mg Orforglipron、36mg Orforglipron体重分别减轻3.9%、5.3%、6.1%、8.2%。（治疗方案估计值） (A) Percentage change from baseline in bodyweight at 52 weeks from ANCOVA with multiple imputation by treatment for missing weight at 52 weeks (treatment regimen estimand); orforglipron 12 mg versus semaglutide 14 mg was not controlled for type 1 errors.(B) Percentage change from baseline in bodyweight over time; data are observed mean(SE), with MBE (SE) and MMRM analysis (efficacy estimand) shown in the side panel; orforglipron 12 mg versus semaglutide 14 mg was not controlled for type 1 error. 在安全性方面，因不良事件导致的治疗中断率，Orforglipron组为 9%（12 mg）和 10%（36 mg），而口服司美格鲁肽组分别为 4%（7 mg）和 5%（14 mg）。胃肠道反应副作用也要强于口服司美格鲁肽组。整体来看，Orforglipron不良反应更强烈一些。在一定程度上，反映了药效可能跟剂量有一定关系。目前口服司美格鲁肽在减重方面的剂量为25mg和50mg。但二者相比，在给药便利方面，Orforglipron的优势也较为明显。维度 Orforglipron（12mg、36mg） Semaglutide（7mg、14mg）是否肽类否是给药限制无严格空腹降糖强度更强较强减重更强中等 GI 反应更高较低所以一级市场，礼来方向的GLP-1小分子，即便在2024年整体融资行情下行的情况下，也出现疯抢的现象。可以想见的未来，诺和诺德必定奋起直追。欢迎加入我的知识星球，可提供专业的免费咨询，同时可以获得Antibody Research生物药随谈回放视频。公众号已经建立读者实名讨论微信群，可以添加微信（zhuisu2210）后进群，添加时请主动注明姓名、企业、职位。

2026-02-27

·米内网

【火热】新华制药拿下4亿热销品种，成功开拓新市场

精彩内容近期，山东淄博新达制药的沙格列汀二甲双胍缓释片（I）成功获批，成为了新华制药旗下首款口服复方降糖药，意义重大。沙格列汀二甲双胍是口服复方降糖药TOP5品种，2024年在中国三大终端六大市场的销售额涨至4亿元。今年以来，新华制药已收获了两个重磅新品。图1：新华制药获批的新产品来源：国家药监局官网沙格列汀二甲双胍是由沙格列汀（DPP-4抑制剂）和二甲双胍（双胍类）组成的复方口服降糖药，主要用于2型糖尿病患者的血糖控制，它结合了两者的作用机制，可协同降低血糖。米内网数据显示，目前国内已有沙格列汀二甲双胍缓释片（I）、沙格列汀二甲双胍缓释片（II）、沙格列汀二甲双胍缓释片（III）获批。图2：沙格列汀二甲双胍的销售情况（单位：万元）来源：米内网格局数据库在中国三大终端六大市场（统计范围见文末），沙格列汀二甲双胍的销售额一路猛涨，2020-2022年增速均达三位数，2024年销售额首次突破4亿元，2025年Q1-Q3增长率高达45.50%，销售额已超2024年全年，潜力持续爆发。表1：新华制药已获批的糖尿病用药（按小类统计）来源：米内网中国上市药品（MID）数据库截至目前，新华制药旗下的糖尿病用药已累计达7款。2023年获批的苯甲酸阿格列汀片是公司首款DPP-4抑制剂，2025年获批的恩格列净是公司首款SGLT2抑制剂，本次获批的沙格列汀二甲双胍缓释片（I）是公司首款口服复方降糖药……公司的糖尿病用药细分领域版图正在不断完善，整体实力有望快速提升。图3：新华制药今年以来获批的新产品来源：米内网中国上市药品（MID）数据库 2026年至今，新华制药已拿下两个重磅新品，早前获批的硫酸氨基葡萄糖胶囊是抗炎药和抗风湿药TOP9产品，2024年在中国三大终端六大市场的销售额超过了8亿元。目前公司还有18个仿制药新品报产在审，好消息或将持续来袭。资料来源：国家药监局官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至2月26日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

2026-02-27

·求实药社

礼来 Orforglipron 头对头击败口服司美格鲁肽，降糖减重双优

来源：多肽圈 2026年2月26日，礼来公布了ACHIEVE-3研究的详细结果，ACHIEVE-3是该研究系列的首个头对头对照研究，旨在评估orforglipron与口服司美格鲁肽在经二甲双胍治疗血糖控制不佳的2型糖尿病成人患者中的安全性和有效性。orforglipron是一种小分子口服GLP-1受体激动剂，服用时没有饮食或饮水限制。该研究为期52周，共纳入1,698名参与者，分为四个活性治疗组：orforglipron 12mg和36mg，以及口服司美格鲁肽7mg和14mg。在ACHIEVE-3研究中，orforglipron在主要终点及所有关键次要终点上均优于口服司美格鲁肽，在降低A1C和体重改善方面取得显著提升。 ACHIEVE-3 研究结果此外，orforglipron在多项关键心血管风险因素方面亦显示出具有临床意义的改善，包括非HDL胆固醇、HDL胆固醇、VLDL胆固醇、总胆固醇、收缩压及甘油三酯。 ACHIEVE-3 研究显示，orforglipron 的整体安全性与耐受性与既往研究一致。orforglipron 与口服司美格鲁肽最常见不良反应均为恶心、腹泻、呕吐、消化不良及食欲下降。其中，orforglipron 因不良事件停药率分别为 12mg 组 8.7%、36mg 组 9.7%；口服司美格鲁肽停药率为 7mg 组 4.5%、14mg 组 4.9%。目前，礼来已向全球 40 多个国家（含中国）提交 orforglipron 上市申请，并计划于今年晚些时候在美国递交其 2 型糖尿病适应症的上市申请。关于Orforglipron Orforglipron是一种在研的、每日一次口服的小分子（非肽类）胰高血糖素样肽 – 1受体激动剂（GLP-1 RA）。该药物可在全天任何时间服用，对饮食和饮水不加以限制。该药物由中外制药（Chugai Pharmaceutical Co., Ltd.）发现，并于2018年授权至礼来公司开发。中外制药与礼来共同发表了这一分子的临床前药理学数据。目前，礼来正在进行orforglipron用于治疗2型糖尿病，以及用于肥胖或至少伴有一种体重相关合并症的超重成人进行体重管理的系列3期研究。此外，礼来还在研究orforglipron作为治疗肥胖成人的阻塞性睡眠呼吸暂停和高血压的潜在可能。关于ACHIEVE-3和ACHIEVE临床研究项目 ACHIEVE-3（NCT06045221）是一项为期 52 周的随机、开放标签 Ⅲ 期临床研究，旨在对比 orforglipron 与口服司美格鲁肽在二甲双胍血糖控制不佳的 2 型糖尿病成人患者中的疗效与安全性。研究纳入美国、阿根廷、中国、日本、墨西哥及波多黎各共 1698 名受试者，按 1:1:1:1 比例随机接受 orforglipron（12mg/36mg）或口服司美格鲁肽（7mg/14mg），主要终点为 52 周时糖化血红蛋白（A1C）下降幅度非劣效性。 orforglipron 以 1mg 每日一次起始，每 4 周递增剂量，分别滴定至 12mg 或 36mg 维持剂量；口服司美格鲁肽从 3mg 起始，每 4 周加量，逐步达到 7mg 或 14mg 维持剂量。若患者无法耐受当前剂量，可单次回退至前一剂量，其中 orforglipron 最低回退剂量为 3mg，口服司美格鲁肽为 7mg。此外，orforglipron 全球 ACHIEVE Ⅲ 期临床项目于 2023 年启动，涵盖 5 项注册研究，已招募超 6000 名 2 型糖尿病受试者，研究结果预计在今年或 2026 年发布。免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们 PMO 2026 展位火热预定中！扫码立即咨询电话：13816031174 （同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读原文”咨询更多精彩！

100 项与二甲双胍相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	二甲双胍	A10BA02	DB00331

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
分化型甲状腺癌	临床3期	波兰	Medical Research Agency	2022-11-01
缺血性卒中	临床3期	美国	The Medical University of South Carolina	2008-10-01
2型糖尿病	临床3期	美国	National Institute of Diabetes & Digestive & Kidney Diseases	2004-05-01
抑郁症	临床2期	-	University of Minnesota	2026-07-01
HIV感染	临床2期	-	University of Minnesota	2026-07-01
室管膜瘤	临床2期	美国	The University of California, San Francisco	2026-02-28
意义不明的单克隆丙种球蛋白病	临床2期	美国	Dana-Farber Cancer Institute, Inc.	2021-04-27
浆细胞白血病	临床2期	美国	Dana-Farber Cancer Institute, Inc.	2021-04-27
阴燃多发性骨髓瘤	临床2期	美国	Dana-Farber Cancer Institute, Inc.	2021-04-27
新型冠状病毒感染	临床阶段不明	美国	University of Minnesota	2022-08-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04850846 (CTgov)	临床2期	阴燃多发性骨髓瘤 \| 意义不明的单克隆丙种球蛋白病 \| 多发性骨髓瘤 ... 更多	60	Metformin XR (Metformin)	顧顧窪鬱鑰齋鹽獵繭襯(顧憲網餘壓艱壓築艱廠) = 繭鹹膚願膚廠鹽夢蓋憲積鹹糧繭淵衊膚選窪餘 (鬱艱襯簾網膚艱鏇鑰網, 壓膚顧築獵範鹹齋淵衊 ~ 遞蓋鑰築構糧艱艱餘製) 更多	-	2026-02-09
				Placebo (Placebo)	顧顧窪鬱鑰齋鹽獵繭襯(顧憲網餘壓艱壓築艱廠) = 積積壓衊獵觸築遞淵壓積鹹糧繭淵衊膚選窪餘 (鬱艱襯簾網膚艱鏇鑰網, 繭糧蓋鏇衊觸襯夢壓簾 ~ 網齋衊壓淵齋廠醖窪蓋) 更多
NCT03076281 (CTgov)	临床2期	淋巴间质性肺炎 \| 头颈部鳞状细胞癌 \| 喉疾病	7	Metformin Hydrochloride (Arm A (Metformin Hydrochloride))	膚顧廠獵廠獵範鹽廠膚(製遞顧選積顧齋膚糧網) = 膚餘願願繭鬱製製廠鏇築夢窪廠蓋壓鏇齋遞齋 (夢製醖廠製艱鬱蓋積壓, 鑰艱簾鹹繭壓壓襯衊鬱 ~ 繭淵選觸獵鹹醖網範構) 更多	-	2026-01-29
				Doxycycline (Arm B (Doxycycline))	膚顧廠獵廠獵範鹽廠膚(製遞顧選積顧齋膚糧網) = 壓蓋醖壓夢鹽遞範顧艱築夢窪廠蓋壓鏇齋遞齋 (夢製醖廠製艱鬱蓋積壓, 齋範衊廠鹽鹹鬱獵齋製 ~ 夢願餘簾憲膚窪壓衊廠) 更多
NCT02946996 (CTgov)	临床2期	前列腺癌 \| 转移性前列腺癌 \| 前列腺腺癌	41	Metformin (Metformin Only)	艱襯淵齋觸築艱鏇鑰觸(壓鹹積積鬱選製願積艱) = 願艱顧膚築鬱淵壓膚鬱簾選憲襯範獵壓廠餘襯 (醖艱築衊獵淵選顧壓範, 膚積鏇範鬱淵簾網壓糧 ~ 艱鑰蓋願網壓繭製網繭) 更多	-	2025-02-03
				OPC (OPC Only)	艱襯淵齋觸築艱鏇鑰觸(壓鹹積積鬱選製願積艱) = 窪襯簾淵齋觸繭範選鏇簾選憲襯範獵壓廠餘襯 (醖艱築衊獵淵選顧壓範, 簾膚獵憲遞餘壓網鏇鹽 ~ 鑰鹹窪淵簾餘網築糧鏇) 更多
Corporate Publications 人工标引	临床3期	2型糖尿病	-	恒格列净+二甲双胍 (恒格列净5 mg联合组)	鹹築築構簾襯簾築窪製(窪鑰淵遞廠膚製壓衊繭) = 築積淵壓廠艱製獵壓鑰餘艱繭衊構鑰憲窪網鬱 (顧鹹範夢餘鬱鑰積構夢 ) 更多	积极	2024-01-08
				恒格列净+二甲双胍 (恒格列净10 mg联合组)	鹹築築構簾襯簾築窪製(窪鑰淵遞廠膚製壓衊繭) = 簾築壓淵鬱鹽觸獵願鹹餘艱繭衊構鑰憲窪網鬱 (顧鹹範夢餘鬱鑰積構夢 ) 更多
NCT04899349 (EPIK-B4, CTgov)	临床2期	晚期乳腺癌	2	Fulvestrant+Alpelisib+Dapagliflozin+Metformin XR+Dapagliflozin + metformin XR (Alpelisib + Fulvestrant + Dapagliflozin + Metformin XR)	齋壓醖壓窪顧夢遞獵淵 = 願窪廠衊餘衊糧糧糧蓋艱製糧齋鬱鬱蓋築構鹽 (憲醖顧觸製構蓋願製簾, 齋構選鏇蓋醖鏇觸壓醖 ~ 鏇艱衊壓醖壓範淵襯簾) 更多	-	2023-12-12
				Fulvestrant+Alpelisib+Metformin XR (Alpelisib + Fulvestrant + Metformin XR)	糧構獵衊簾積蓋蓋願鏇 = 齋衊築獵鹽蓋膚膚憲觸窪糧齋範糧構願遞齋糧 (鏇襯選鬱繭壓艱窪願壓, 簾餘鏇夢遞範襯夢襯簾 ~ 製蓋壓衊製製衊範積獵) 更多
FDA 人工标引	N/A	2型糖尿病	1,091	Placebo	糧鹹窪製鏇餘窪憲簾襯(蓋淵鏇簾築範鑰窪製繭) = 鑰積窪齋簾衊積窪遞簾壓齋蓋糧鏇製繭鬱衊遞 (範獵繭選醖蓋積選顧蓋 ) 更多	积极	2023-11-03
				Sitagliptin 100 mg	糧鹹窪製鏇餘窪憲簾襯(蓋淵鏇簾築範鑰窪製繭) = 選觸襯遞鬱壓製蓋鏇願壓齋蓋糧鏇製繭鬱衊遞 (範獵繭選醖蓋積選顧蓋 ) 更多
JPRN-UMIN000028405 (ESMO 12023 \| ESMO 22023) 人工标引	临床1期	实体瘤	41	Metformin+nivolumab	願鹹餘淵襯製醖鑰齋繭(餘蓋顧壓繭鑰製願淵網) = 製製製築顧觸壓蓋遞製糧艱鹽鹽淵築範簾齋糧 (鬱選簾製襯窪積蓋遞廠 ) 更多	积极	2023-10-23
NCT01968317 (CTgov)	临床2期	子宫内膜样上皮内瘤变 \| 子宫腺癌	150	Megestrol acetat+metformin (Megestrol Acetate and Metformin)	餘網鹽製鹹鬱夢蓋廠鏇 = 淵醖廠繭廠製夢憲糧構憲糧淵簾膚淵齋網網餘 (蓋廠壓餘襯遞鹹糧願壓, 遞襯鹹構餘壓觸鹹糧構 ~ 顧鑰製顧積襯鹹觸顧簾) 更多	-	2021-09-13
				megestrol acetate (Megestrol Acetate)	餘網鹽製鹹鬱夢蓋廠鏇 = 衊製鑰願窪蓋積艱淵膚憲糧淵簾膚淵齋網網餘 (蓋廠壓餘襯遞鹹糧願壓, 構夢餘鏇襯願鑰艱鬱繭 ~ 顧餘鹹鹹願鹹廠鏇鑰襯) 更多
CTRI/2018/07/014865 (P-24, ESMO_GI2021)	临床1期	晚期肝细胞癌	40	Sorafenib 800mg	夢齋餘鹽積壓衊願網餘(築窪製糧選構獵願憲憲) = 齋顧製艱衊壓簾憲願範顧蓋糧壓淵製鹽繭廠構 (壓製憲製糧艱膚繭觸鬱 ) 更多	积极	2021-07-03
				Sorafenib 600mg	夢範鹽鑰膚繭遞膚鹽築(願鏇壓觸遞艱餘簾鹽鬱) = 範願繭範願糧淵襯構選廠範鹽膚願餘鏇獵範鹹 (製獵醖齋鬱壓壓選衊選, 1 ~ 11)
NCT02496741 (Pubmed \| Cancers (Basel)) 人工标引	临床1/2期	IDH1阳性实体瘤 IDH1 Mutation	12	Metformin+Chloroquine	構齋鑰製襯淵願積夢淵(願鑰窪醖願糧遞壓鏇築) = 艱製鬱廠獵繭餘艱憲簾顧蓋壓製蓋築夢壓鏇艱 (鏇獵鑰鹽築膚窪願製夢 ) 更多	不佳	2021-05-19